Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
8.72
USD
|
+2.59%
|
|
+14.59%
|
+113.73%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,833
|
750.2
|
804.3
|
1,930
|
-
|
-
|
Enterprise Value (EV)
1 |
2,691
|
750.2
|
703.2
|
1,767
|
1,645
|
1,506
|
P/E ratio
|
-7.23
x
|
-2.76
x
|
-2.79
x
|
-7.69
x
|
-6.97
x
|
-5.86
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-7.78
x
|
-2.92
x
|
-2.62
x
|
-9
x
|
-5.86
x
|
-1.56
x
|
EV / FCF
|
-9.58
x
|
-
|
-2.57
x
|
-9.85
x
|
-8.31
x
|
-6.58
x
|
FCF Yield
|
-10.4%
|
-
|
-38.9%
|
-10.2%
|
-12%
|
-15.2%
|
Price to Book
|
4.03
x
|
-
|
2.81
x
|
4
x
|
4.23
x
|
-
|
Nbr of stocks (in thousands)
|
183,042
|
189,920
|
197,132
|
221,323
|
-
|
-
|
Reference price
2 |
15.48
|
3.950
|
4.080
|
8.720
|
8.720
|
8.720
|
Announcement Date
|
3/16/22
|
3/16/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-280.2
|
-345.8
|
-256.9
|
-268.6
|
-196.5
|
-280.6
|
-965.7
|
EBIT
1 |
-
|
-286.1
|
-356.9
|
-272.6
|
-293.1
|
-264.7
|
-317
|
-500
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-285.3
|
-355.9
|
-269.5
|
-283.3
|
-246.2
|
-318.2
|
-495.8
|
Net income
1 |
-130.8
|
-285.3
|
-355.9
|
-269.5
|
-283.3
|
-241.4
|
-308.2
|
-479.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-6.670
|
-21.92
|
-2.140
|
-1.430
|
-1.460
|
-1.134
|
-1.250
|
-1.488
|
Free Cash Flow
1 |
-
|
-161.9
|
-280.9
|
-
|
-273.6
|
-179.5
|
-198
|
-229
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/20
|
3/24/21
|
3/16/22
|
3/16/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-28.07
|
-69.1
|
-82.17
|
-
|
-79.71
|
-111.8
|
-
|
-79.36
|
-51.65
|
-43.08
|
-37.96
|
-
|
EBIT
1 |
-83.43
|
-111.3
|
-31.68
|
-72.9
|
-86.19
|
-81.79
|
-84.05
|
-116.3
|
-2.181
|
-90.62
|
-68.62
|
-65.67
|
-65.3
|
-65.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-83.26
|
-110.7
|
-31.45
|
-72.46
|
-85.12
|
-80.44
|
-82.12
|
-114
|
0.984
|
-88.12
|
-71.08
|
-69.14
|
-69.97
|
-71.18
|
Net income
1 |
-83.26
|
-110.7
|
-31.45
|
-72.46
|
-85.12
|
-80.44
|
-82.12
|
-114
|
0.984
|
-88.12
|
-71.08
|
-69.14
|
-69.97
|
-71.18
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4600
|
-0.6000
|
-0.1700
|
-0.3900
|
-0.4500
|
-0.4200
|
-0.4300
|
-0.5900
|
-
|
-0.4500
|
-0.3200
|
-0.2860
|
-0.2760
|
-0.2800
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
3/16/22
|
5/10/22
|
8/4/22
|
11/2/22
|
3/16/23
|
5/8/23
|
8/3/23
|
11/8/23
|
2/29/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
52.9
|
142
|
-
|
101
|
162
|
285
|
424
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-162
|
-281
|
-
|
-274
|
-180
|
-198
|
-229
|
ROE (net income / shareholders' equity)
|
-
|
-80.8%
|
-194%
|
-
|
-72%
|
-62.3%
|
-50.3%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-49.8%
|
-32.1%
|
-
|
-40.8%
|
-36.9%
|
-33.2%
|
-
|
Assets
1 |
-
|
572.8
|
1,110
|
-
|
694
|
654.1
|
927.3
|
-
|
Book Value Per Share
2 |
-
|
-
|
3.840
|
-
|
1.450
|
2.180
|
2.060
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
23.9
|
29.9
|
-
|
20
|
11.5
|
12
|
7
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/20
|
3/24/21
|
3/16/22
|
3/16/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
8.72
USD Average target price
11.17
USD Spread / Average Target +28.06% Consensus |
1st Jan change
|
Capi.
|
---|
| +113.73% | 1.93B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|